FindTrial
Sign In

Valemetostat

DRUG8 trials

Sponsors

Celgene, M.D. Anderson Cancer Center, National Cancer Institute (NCI), University of Alabama at Birmingham, Memorial Sloan Kettering Cancer Center

Conditions

Aggressive Variant Prostate CarcinomaBreast CancerCastration-Resistant Prostate CarcinomaExtensive-stage Small-cell Lung CancerHead and Neck CancerHead and Neck CarcnimonaHead and Neck Squamous Cell CarcinomaHepatocellular Carcinoma

Phase 1

A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)
Active, not recruitingNCT03930953
CelgeneLymphoma, Non-Hodgkin
Start: 2019-05-20End: 2028-02-09Target: 438Updated: 2026-02-19
DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers
Active, not recruitingNCT04388852
M.D. Anderson Cancer CenterAggressive Variant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma +7
Start: 2020-08-20End: 2026-12-31Updated: 2026-05-20
Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast Cancer
Active, not recruitingNCT05633979
M.D. Anderson Cancer CenterBreast Cancer
Start: 2023-02-09End: 2032-12-31Updated: 2026-01-20
A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma
RecruitingNCT05683171
M.D. Anderson Cancer CenterLymphoma
Start: 2023-05-19End: 2027-09-30Target: 60Updated: 2026-05-15
Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamous Cell Carcinoma (SCC) of the Head and Neck: The PANTHERAS
WithdrawnNCT05879484
National Cancer Institute (NCI)Head and Neck Cancer, Head and Neck Carcnimona, Head and Neck Squamous Cell Carcinoma +3
Start: 2025-07-09End: 2025-07-09Updated: 2025-07-10
A Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in HCC
RecruitingNCT06294548
University of Alabama at BirminghamHepatocellular Carcinoma
Start: 2025-07-29End: 2028-08-28Target: 45Updated: 2025-08-11
A Study of Valemetostat in Combination With Atezolizumab in People With Lung Cancer
RecruitingNCT06807632
Memorial Sloan Kettering Cancer CenterExtensive-stage Small-cell Lung Cancer
Start: 2025-01-29End: 2027-01-01Target: 24Updated: 2026-04-01
A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)
RecruitingNCT07244341
Daiichi SankyoMetastatic Castration-resistant Prostate Cancer
Start: 2025-12-03End: 2029-11-30Target: 60Updated: 2026-05-15

Related Papers

A phase Ib/II, dose escalation and dose expansion study of valemetostat tosylate (DS-3201b) with atezolizumab and bevacizumab in advanced hepatocellular carcinoma (HCC).
Journal of Clinical Oncology2026-01-10
Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, ± rituximab (R) in patients with Relapsed/Refractory follicular lymphoma (R/R FL): Phase 1/2 study extended follow-up Results
Blood2025-11-03
Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, ± rituximab (R) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Phase 1/2 study extended follow-up Results
Blood2025-11-03
Golcadomide (GOLCA) ± Rituximab (RTX) Demonstrates Durable Efficacy and Is Well Tolerated in Patients (pts) with Relapsed/Refractory Follicular Lymphoma (R/R FL): Updated Results from the Phase 1/2 CC-99282-NHL-001 Study
Blood2024-11-053 citations
Phase 1b study of EZH1/2 inhibitor valemetostat in combination with trastuzumab deruxtecan in patients with HER2 low/ultra-low/null metastatic breast cancer.
Journal of Clinical Oncology2024-06-01
Abstract PO3-19-10: Phase 1b study of EZH1/2 inhibitor valemetostat in combination with trastuzumab deruxtecan in subjects with HER2 low/ultra-low/null metastatic breast cancer
Cancer Research2024-05-02
Efficacy and Safety of Golcadomide, a Novel Cereblon E3 Ligase Modulator (CELMoD) Agent, Combined with Rituximab in a Phase 1/2 Open-Label Study of Patients with Relapsed/Refractory Non-Hodgkin Lymphoma
Blood2023-11-0212 citations
Valemetostat for Relapsed or Refractory B-Cell Lymphomas: Primary Results from a Phase 1 Trial
Blood2023-11-024 citations
Investigation of the Synergistic Combination of a Novel Celmod (CC-99282) and BET Inhibitors in Preclinical DLBCL
Blood2023-11-021 citations
OPEN‐LABEL PHASE 1/2 STUDY OF CC‐99282, A CEREBLON E3 LIGASE MODULATOR (CELMOD) AGENT ± RITUXIMAB, IN PATIENTS WITH RELAPSED/REFRACTORY (<i>R</i>/<i>R</i>) NON‐HODGKIN LYMPHOMA (NHL)
Hematological Oncology2023-06-011 citations
Elucidating the Molecular Mechanisms of Action of CC-99282, a Novel Cereblon (CRBN) E3 Ligase Modulator (CELMoD) Agent, Via Genome-Wide CRISPR Screen in a Preclinical Model of Non-Hodgkin Lymphoma (NHL)
Blood2022-11-152 citations
Association of Immune Dynamics and Treatment Outcome in Patients (pts) with Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL) Treated with the Novel Cereblon (CRBN) E3 Ligase Modulator (CELMoD) Agent CC-99282
Blood2022-11-15
Abstract 3932: Pathway interaction and mechanistic synergy of CC-99282, a novel cereblon E3 ligase modulator (CELMoD) agent, with enhancer of zeste homolog 2 inhibitors (EZH2is)
Cancer Research2022-06-152 citations
S216: CLINICAL ACTIVITY OF CC-99282, A CEREBLON E3 LIGASE MODULATOR (CELMOD) AGENT, IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA (R/R NHL) – RESULTS FROM A PHASE 1, OPEN-LABEL STUDY
HemaSphere2022-06-014 citations
Clinical Activity of CC-99282, a Novel, Oral Small Molecule Cereblon E3 Ligase Modulator (CELMoD) Agent, in Patients (Pts) with Relapsed or Refractory Non-Hodgkin Lymphoma (R/R NHL) - First Results from a Phase 1, Open-Label Study
Blood2021-11-0520 citations
A PHASE 1, MULTICENTER, OPEN‐LABEL STUDY OF CC‐99282 ALONE AND IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY NON‐HODGKIN LYMPHOMAS
Hematological Oncology2021-06-011 citations